Literature DB >> 21051852

Management of recurrent vulvo-vaginal candidosis as a chronic illness.

Gilbert G G Donders1, Gert Bellen, Werner Mendling.   

Abstract

For sporadic acute Candida vaginitis, any oral or local antifungal therapy can be used. For women with recurrent vulvo-vaginal candidosis (RVC), on the other hand, such simple approaches are insufficient, regardless of the product chosen. Instead, RVC should be managed as any other chronic disease and requires long-term, prophylactic, suppressive antifungal treatment. A regimen using individualized, decreasing doses of oral fluconazole (the ReCiDiF regimen) was proven to be highly efficient and offered great comfort to the patients. During this regimen, it is crucial that patients are carefully examined by anamnestic, clinical, microscopic and culture-proven absence of Candida. If a relapse occurs, the medication is adjusted and efforts are taken to find a possible triggering factor for the reactivation of the infection. Care has to be taken not to accumulate 'don't do's', unless the efficiency of a measure has been proven, by trying to eliminate one risk factor at a time for 2 months. Known possible triggers to be kept in mind are (1) antibiotic use, (2) use of specific contraceptives, especially combined contraceptive pills, (3) disturbed glucose metabolism, (4) the use of personal hygienic products, and (5) tight clothing or plastic panty liners. In therapy-resistant cases, non-albicans infection must be ruled out, and alternative therapies should be tried. Boric acid is proven to be efficient in most of these resistant cases, but other non-azoles like amphotericin B, flucytosine, gentian violet, and even caspofungin may have to be tried. As a final remark it has to be said that many patients feel poorly understood and inefficiently managed by many care-givers, increasing their feelings of guilt and sexual inferiority. Therefore, attention has to be given to take the disease seriously, follow strict treatment regimens, and advise precisely and based on individual evidence concerning any possible risk factors for recurrence. In case of therapy-resistant vulvo-vaginitis, reconsider your diagnosis and/or consider referral to specialized therapists.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051852     DOI: 10.1159/000314022

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  13 in total

1.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

2.  Genotyping reveals no link between Candida albicans genotype and vaginitis severity in Turkish women.

Authors:  Ahmet Barış Güzel; Aylin Döğen; Merve Aydın; Ayşe Serin; Mehmet Sami Serin; Ayşe Kalkancı; Macit Ilkit
Journal:  Mycopathologia       Date:  2013-04-02       Impact factor: 2.574

3.  In vitro anti-Candida activity of lidocaine and nitroglycerin: alone and combined.

Authors:  Ana Palmeira-de-Oliveira; Ana Rita Ramos; Carlos Gaspar; Rita Palmeira-de-Oliveira; Paula Gouveia; José Martinez-de-Oliveira
Journal:  Infect Dis Obstet Gynecol       Date:  2012-05-20

4.  Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA.

Authors:  Samuel Aballéa; Florent Guelfucci; Julian Wagner; Amine Khemiri; Jean-Paul Dietz; Jack Sobel; Mondher Toumi
Journal:  Health Qual Life Outcomes       Date:  2013-10-11       Impact factor: 3.186

Review 5.  Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.

Authors:  Sanjay Kalra; Sujoy Ghosh; A H Aamir; Md Tofail Ahmed; Mohammod Feroz Amin; Sarita Bajaj; Manash P Baruah; Uditha Bulugahapitiya; A K Das; Mimi Giri; Sonali Gunatilake; Saeed A Mahar; Md Faruque Pathan; Nazmul Kabir Qureshi; S Abbas Raza; Rakesh Sahay; Santosh Shakya; Dina Shreshta; Noel Somasundaram; Manilka Sumanatilleke; A G Unnikrishnan; Achini Madushani Wijesinghe
Journal:  Indian J Endocrinol Metab       Date:  2017 Jan-Feb

6.  Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of Candida species.

Authors:  Ali Rezaei-Matehkolaei; Shokoofe Shafiei; Ali Zarei-Mahmoudabadi
Journal:  Iran J Microbiol       Date:  2016-12

7.  Mannose-Binding Lectin Gene Polymorphism and Its Association with Susceptibility to Recurrent Vulvovaginal Candidiasis.

Authors:  Noha M Hammad; Nissreen E El Badawy; Ashraf M Nasr; Hamed A Ghramh; Laila M Al Kady
Journal:  Biomed Res Int       Date:  2018-04-04       Impact factor: 3.411

Review 8.  The Role of Fatty Acid Metabolites in Vaginal Health and Disease: Application to Candidiasis.

Authors:  Silke Baldewijns; Mart Sillen; Ilse Palmans; Paul Vandecruys; Patrick Van Dijck; Liesbeth Demuyser
Journal:  Front Microbiol       Date:  2021-07-02       Impact factor: 5.640

9.  BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial.

Authors:  Melinda Zeron Mullins; Konia M Trouton
Journal:  Trials       Date:  2015-07-26       Impact factor: 2.279

10.  Identification of a strong and specific antichlamydial N-acylhydrazone.

Authors:  Huirong Zhang; Anuj Kunadia; Yingfu Lin; Joseph D Fondell; Daniel Seidel; Huizhou Fan
Journal:  PLoS One       Date:  2017-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.